Hyundai Everdigm Corp. (KOSDAQ:041440)
8,850.00
-130.00 (-1.45%)
At close: Feb 20, 2026
Hyundai Everdigm Revenue
Hyundai Everdigm had revenue of 64.73B KRW in the quarter ending September 30, 2025, with 5.92% growth. This brings the company's revenue in the last twelve months to 365.16B, up 26.18% year-over-year. In the year 2024, Hyundai Everdigm had annual revenue of 355.12B, down -0.82%.
Revenue (ttm)
365.16B
Revenue Growth
+26.18%
P/S Ratio
0.43
Revenue / Employee
613.72M
Employees
595
Market Cap
157.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 355.12B | -2.93B | -0.82% |
| Dec 31, 2023 | 358.05B | -16.39B | -4.38% |
| Dec 31, 2022 | 374.44B | 56.58B | 17.80% |
| Dec 31, 2021 | 317.86B | 54.38B | 20.64% |
| Dec 31, 2020 | 263.49B | 14.87B | 5.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DASAN Networks | 498.45B |
| KX Innovation | 349.25B |
| Kumyang Green Power | 231.89B |
| KUKJEON PHARMACEUTICAL | 132.97B |
| OPTUS Pharmaceutical | 87.58B |
| LB Investment | 36.94B |
| WISEnut | 35.74B |
| Seoul Auction | 19.60B |